IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

Phase 2

Phase 3

IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal MelanomaIDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Sponsor:

IDEAYA Biosciences

Code:

NCT05987332

Conditions

Metastatic Uveal Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

IDE196

Crizotinib

Pembrolizumab

Ipilimumab

Nivolumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-28. This information was provided to ClinicalTrials.gov by IDEAYA Biosciences on 2025-03-28.